<code id='2FA91CBEBD'></code><style id='2FA91CBEBD'></style>
    • <acronym id='2FA91CBEBD'></acronym>
      <center id='2FA91CBEBD'><center id='2FA91CBEBD'><tfoot id='2FA91CBEBD'></tfoot></center><abbr id='2FA91CBEBD'><dir id='2FA91CBEBD'><tfoot id='2FA91CBEBD'></tfoot><noframes id='2FA91CBEBD'>

    • <optgroup id='2FA91CBEBD'><strike id='2FA91CBEBD'><sup id='2FA91CBEBD'></sup></strike><code id='2FA91CBEBD'></code></optgroup>
        1. <b id='2FA91CBEBD'><label id='2FA91CBEBD'><select id='2FA91CBEBD'><dt id='2FA91CBEBD'><span id='2FA91CBEBD'></span></dt></select></label></b><u id='2FA91CBEBD'></u>
          <i id='2FA91CBEBD'><strike id='2FA91CBEBD'><tt id='2FA91CBEBD'><pre id='2FA91CBEBD'></pre></tt></strike></i>

          Home / entertainment / explore

          explore


          explore

          author:hotspot    Page View:2
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In